JPMorgan Upgrades Solid Biosciences Stock, Sees Growth Potential

JPMorgan upgraded Solid Biosciences stock, a biotechnology company that acquired UF startup AavantiBio, from Neutral to Overweight, and increased the price target to $15.00 from the previous $10.00. The firm’s decision reflects a positive outlook on the company’s prospects, particularly with upcoming developments expected in the fourth quarter.

Solid Biosciences, which specializes in gene therapy and rare diseases and incubated at UF Innovate | Accelerate, is anticipated to release initial data on SGT-003, one of its key pipeline products, later this year. The analyst from JPMorgan expressed confidence in the company’s position, citing the favorable regulatory environment in the U.S. for gene therapy and rare diseases as a supportive factor for the company’s growth.

The upgraded rating is based on the potential of Solid Biosciences’ pipeline, which goes beyond SGT-003. According to JPMorgan, the broader range of gene therapy products under development could provide additional upside for investors. The firm also considers the current valuation of SLDB shares to be undervalued when the probability-adjusted potential of SGT-003 is taken into account.

Read more about JPMorgan Upgrades Solid Biosciences Stock, Sees Growth Potential.